血栓通与阿司匹林对ITGB3基因多态性药物抵抗患者治疗作用的研究
Therapeutical Effects of Aspirin and XueShuanTong on Patients with the Drug Resistance of ITGB3 Genes Polymorphism
-
摘要: 目的 探讨中药制剂血栓通及阿司匹林抗血小板治疗脑卒中以及ITGB3基因多态性对治疗效果的相关性。方法 收集了192例脑梗死患者，随机分为4组（阿司匹林组、血栓通组、血栓通+阿司匹林组、阿司匹林+氯吡格雷组）进行治疗，通过一般资料及测定生化指标和血栓弹力图，同时提取静脉血全基因组DNA，采用Snapshot方法检测ITGB3 基因型，分析4组患者的血小板抑制情况，比较各组结果。结果 整体水平上，各组经药物治疗后，血小板抑制率显著提高，血栓通治疗对3种ITGB3基因型AA、AG、GG患者血小板抑制率显著高于阿司匹林组，且组间没有显著性差异。结论 中药制剂血栓通可以抑制血小板聚集发挥药效，并且突变型ITGB3基因AA及GG不会对血栓通产生抵抗。Abstract: OBJECTIVE To investigate the relationship between ITGB3 gene polymorphism and therapeutic effects of XueShuanTong and aspirin on cerebral infarction with anti-platelet. METHODS 192 patients with cerebral infarction were collected and randomly divided into 4 groups. According to patients general information， biomedical index and thromboelastogram， DNA genome were extracted from venous blood and detected by using Snapshot method， and then analyzed the situations of anti-platelet and compared the results of 4 groups. RESULTS Generally， the inhibitory ratio of platelet increased obviously after the patients were treated with drugs. Compared with aspirin group， the inhibitory ratio of platelet increased obviously in patients with ITGB3 genes(AA， AG， GG) treated by XueShuanTong pharmaceutics， and no significant difference appeared among these 3 groups. CONCLUSION XueShuanTong pharmaceutics can inhibit platelet aggregation， which will prevent the drug resistance in patients with mutant ITGB3 genes(AA and GG).
-
Key words:
- ITGB3 /
- aspirin /
- XueShuanTong /
- genes polymorphism
-
[1] 中华医学会神经病学分会脑血管病学组缺血性脑卒中二级预防指南撰写组. 中国缺血性脑卒中和短暂性脑缺血发作二级预防指南[J]. 中华神经科杂志， 2010， 43(2): 154-160.Neurology Branch of Chinese Medical Association Cardiovascular Epidemiology Group. Ischemic stroke and transient ischemic attack China secondary prevention guide[J]. Chin J Neurol， 2010， 43(2): 154-160. [2] 司全金，李开亮. 老年患者应用抗血小板药物的收益与风险[J]. 中华老年心脑血管病杂志， 2013， 15(8) : 787-788.SI QJ， LI KL. Elderly patients with use of antiplatelet drugs benefits and risks[J]. Chin J Geriatr Heart Brain Vessel Dis， 2013， 15(8) : 787-788. [3] 汪芳. 阿司匹林在心血管疾病一级预防中的研究进展与指南规范分析[J]. 中国全科医学， 2015， 18(29) : 3519-3523.WANG F．Research progress and guide standard of aspirin in the primary prevention of cardiovascular diseases[J]．Chin Gener Pract，2015，18 ( 29) : 3519-3523. [4] HANKEY GJ，EIKELBOOM JW.Aspirin resistance[J].Lancet， 2006， 367(9510): 606-617. [5] PAPP E， HAVASI V， BENE J， et al.Glycoprotein IIIA gene (PlA) polymorphism and aspirin resistance is there any correlation [J]. Ann Pharmacother， 2005， 39(6): 1013-1018. [6] KNOWLES JW， WANG H， ITAKURA H， et al. Association of polymorphisms in platelet and hemostasis system genes with acute myocardial infarction[J].Am Heart J， 2007， 154(6): 1052-1058. [7] 陈翔， 袁小梅. 氯吡格雷联合氟伐他汀治疗脑梗死对患者Barthel指数及NIHSS评分的影响[J]. 中国药业， 2016，25(22): 59-61.CHEN X， YUAN XM. Effect of clopidogrel combined with fluvastatin on barthel index and NIHSS score of patients with cerebral infarction[J]. China Pharmaceut， 2016，25(22): 59-61. [8] 刘玲， 侯华娟， 刘亚红， 等. 用血栓弹力图评价阿司匹林及氯吡格雷在缺血性卒中患者中血小板抑制效应的研究[J]. 中风与神经疾病杂志， 2012，29(5): 446-449.LIU L，HOU HJ， LIU YH， et al. Evaluation inhibitory effects of different antiplatelet agents on platelets in ischemi cerebral vascular disease patients by thrombelastogram[J]. J Apopl Nerv Dis， 2012，29(5): 446-449. [9] SANTOSO S， KIEFEL V. Human platelet-specific alloantigens: update[J]. Vox Sang， 1998， 74(2): 249-253. 〖JP〗 -
点击查看大图
计量
- 文章访问数: 1289
- HTML全文浏览量: 7
- PDF下载量: 1217
- 被引次数: 0
下载:
